IMMUNOPRECISE ANTIBODIES LTD - IPA STOCK NEWS

ImmunoPrecise Antibodies (IPA) reported financial results for Q1 FY25, ending July 31, 2024. The company achieved $5.3 million in revenue, with two of its three sites showing double-digit growth. IPA's AI-driven platform, LENSai, successfully developed antibodies end-to-end using computer simulations for a challenging Tumor Microenvironment target. BioStrand is expanding its presence on the AWS Marketplace, potentially opening new revenue streams. Talem Therapeutics and BioStrand are collaborating to enhance lead therapeutic assets using LENSai.

Financial highlights include:

• Project revenue: $4.9 million
• R&D expenses: $1.6 million
• Net loss: $4.0 million or $(0.15) per share
• Cash balance: $4.0 million as of July 31, 2024

ImmunoPrecise Antibodies (IPA), an AI-driven biotherapeutic research company, has announced its upcoming financial results and business highlights for Q1 FY2025. The company will host a conference call and webcast on September 16, 2024, at 10:30 AM ET to discuss these results. IPA will issue a press release with financial details prior to the call.

Participants can join the conference call via various dial-in numbers or through a webcast link available on the company's IR pages. The event will include a Q&A session following management's presentation. Investors are encouraged to review IPA's periodic reports for a comprehensive understanding of the company's operations and financial condition.

ImmunoPrecise Antibodies (NASDAQ: IPA) has announced its participation in the H.C. Wainwright's 26th Annual Global Investment Conference from September 9-11, 2024. The event will be held both in-person at the Lotte New York Palace Hotel in Manhattan and virtually. IPA's management team will be conducting one-on-one meetings with investors and interested parties.

The conference provides a platform for companies in sectors like biotech and life sciences to network, present, and meet with investors. Admission is free for qualified investors. Those interested in scheduling appointments with IPA can contact Jennifer K. Zimmons at Quantum Media. For registration and more information, visit the HCW Events website.

ImmunoPrecise Antibodies (IPA), an AI-driven biotherapeutics company, has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement. The notification, received on August 19, 2024, states that IPA's common shares closed below $1.00 for 30 consecutive business days from July 5 to August 15, 2024, violating Nasdaq Rule 5450(a)(1). This notification does not immediately affect IPA's listing or trading status on Nasdaq and is not a notice of imminent delisting. The company now has a specified period to regain compliance by meeting the minimum bid price requirement.

ImmunoPrecise Antibodies (IPA) has achieved a significant milestone in antibody engineering using its LENSai technology. The company successfully engineered highly specific antibodies to target a tumor microenvironment protein with previously unknown structure, entirely through computer simulations. This breakthrough demonstrates LENSai's potential to revolutionize drug discovery by:

1. Overcoming the challenge of designing therapeutics without prior structural knowledge
2. Producing antibodies that bind exclusively to the oncology target under specific conditions
3. Avoiding binding to similar proteins on healthy cells, potentially reducing side effects

This achievement could lead to faster, more efficient, and cost-effective development of targeted cancer therapies, addressing the industry's high failure rates and lengthy development timelines.

ImmunoPrecise Antibodies (IPA) reported record revenue of $24.5 million for fiscal year 2024, a 19% increase from the previous year. The company achieved significant milestones, including:

1. Expansion of laboratory facilities in Oss, Netherlands
2. Launch of commercial LENSai API for AI-powered solutions
3. Strategic collaborations with InterSystems and PGxAI
4. Introduction of advanced AI models for drug discovery

Despite the revenue growth, IPA reported a net loss of $27.2 million, including a $15 million impairment charge related to BioStrand's goodwill and intangible assets. The company's cash position stood at $3.5 million as of April 30, 2024, with reduced cash burn compared to the previous year.

ImmunoPrecise Antibodies (NASDAQ: IPA) has rescheduled its fiscal year 2024 financial results and business highlights release from July 25 to July 29, 2024. The company will host an earnings conference call via webcast at 10:30 am Eastern Time on the same day. The delay is to allow auditors additional time to complete valuation calculations on goodwill and intangible assets, ensuring accurate financial data and regulatory compliance.

Investors can access the live audio webcast through IPA's Investor Relations website. Participants can join the conference call using the provided toll-free and international dial-in numbers, using the Conference ID 9236374. A replay of the call will be available on the company's website following the conference.

ImmunoPrecise Antibodies (IPA) has entered into a $3.0 million convertible debenture agreement with Yorkville Advisors Global, LP. The deal includes two tranches: $2.0 million completed on July 16, 2024, and $1.0 million pending SEC approval. Key features:

- 8.0% annual interest rate
- Convertible to common shares at the lower of $1.16 or 95% of the lowest 10-day VWAP
- Redeemable if stock price is below $1.16
- Monthly payments required if stock price falls below $0.20
- Conversion to $300,000 per 30-day period if price is below $1.16

Proceeds will be used for R&D, capital expenditures, and working capital. Clear Street acted as placement agent.

ImmunoPrecise Antibodies (IPA), an AI-driven biotherapeutic research and technology company, has announced it will release its financial results and business highlights for the fourth quarter and fiscal year 2024 on July 25th, 2024. The company will host an earnings conference call via webcast at 10:30 AM Eastern Time on the same day.

Investors can access the live audio webcast through a link on IPA's Investor Relations website. A replay will be available after the call. Participants can join the conference call using provided toll-free and international dial-in numbers, using the Conference ID 9236374 or Conference Name.